Category: Advocacy news
From bedside to Brussels: hematology at the forefront of EU health policy
EHA's experts are currently front and center in several important EU initiatives that will help improve conditions for, and patient access to, innovation in hematology.
Update on EU4Health Calls and Contracts for 2024
The European Health and Digital Executive Agency (HaDEA) has published the tentative calendar for the EU4Health program calls and contracts for 2024.
Recap: European Affairs and Hematology at EHA2024
As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.
Parliament puts final stamp on the European Health data Space
On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS).
EU Parliament agrees on pharmaceutical legislation stance
On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.
Cancer Medicines Forum workshop April 5: a way forward for treatment optimizatio…
The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).
EHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU adv…
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Belgium shares EU health priorities for Council Presidency
On December 8, Belgium held a conference to unveil its program for the upcoming Council of the EU Presidency (website), to start on January 1, 2024.
EHA response to the EU’s Pharma Revision
Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation.
Hematology and oncology, pacemakers for EU HTA
EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).
Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and…
The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.
New HemaSphere publication on IVDR implementation
The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU,…
Moldova to be allowed to participate in EU4Health projects
The European Commission and the Government of the Republic of Moldova have signed an agreement to associate Moldova with the EU4Health program.
EU calls for proposal 2023
IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027.